

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 10/646,904

**Applicant** 

: Herbert Irschik et al.

Filed

: August 22, 2003

Title

: Use of Disorazoles and Their Derivatives for the Treatment of

Benign And Malignant Oncoses

Attorney Docket No. : (old) 103832-510-PRO; (new) 103832-510-NP

Mail Stop Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08 (substitute for form 1449/PTO). A copy of each listed document is enclosed. All of Documents 1-6 are cited in the specification of the patent application.

Document 1 is in both German and English.

Documents 2-5 are in English.

Document 6 is in German. An English translation of the Summary section of the document is attached to the document.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and return a copy to Applicant.

This Information Disclosure Statement is being filed before the mailing of a first office action, and therefore no fee is necessary. However, the Commissioner is still authorized to charge the required fees, if any, to Deposit Account 06-0923.

Respectfully submitted,

Eva Tan (Reg. No. 46,406)

Goodwin Procter LLP 103 Eisenhower Parkway

Roseland, NJ 07068

(973) 992-1990 Ext. 7904

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Uter the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

TRADE Mobile Stitute for form 1449B/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

NI

Filing Date
August 22, 2003

First Named Inventor
Art Unit

10/646,904

August 22, 2003

Herbert Irschik et al.

Complete if Known

(Use as many sheets as necessary) Examiner Name

Attorney Docket Number 103832-510-NP

Examiner Initials*  Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  G. Hofle, annual report 1999/2000 of the Gesellschaft fur Biotechnologische Forschung (Association for Biotechnological Research) GBF, 95-110  2 Yue-Zhong Shu, J. Nat. Prod., 1998, 61, 1053-1071.  3 V. J. Ram and S. Kumari, Drug News Perspect, 2001, 14(8), 465-482.  4 R. Jansen et al., Liebigs Ann. Chem., 1994, (8), 759-773.  5 H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.  6 Y. A. Elnakady, Dissertation, T.U. Braunschweig, 2001.	NON PATENT LITERATURE DOCUMENTS						
1 Biotechnological Research] GBF, 95-110  2 Yue-Zhong Shu, J. Nat. Prod., 1998, 61, 1053-1071.  3 V. J. Ram and S. Kumari, Drug News Perspect, 2001, 14(8), 465-482.  4 R. Jansen et al., Liebigs Ann. Chem., 1994, (8), 759-773.  5 H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.		ials* No.1 magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, and/or country where published.					
3 V. J. Ram and S. Kumari, Drug News Perspect, 2001, 14(8), 465-482.  4 R. Jansen et al., Liebigs Ann. Chem., 1994, (8), 759-773.  5 H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.		1					
4 R. Jansen et al., Liebigs Ann. Chem., 1994, (8), 759-773.  5 H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.		2	Yue-Zhong Shu, J. Nat. Prod., 1998, 61, 1053-1071.				
5 H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.		3	V. J. Ram and S. Kumari, Drug News Perspect, 2001, 14(8), 465-482.				
		4	R. Jansen et al., Liebigs Ann. Chem., 1994, (8), 759-773.				
6 Y. A. Elnakady, Dissertation, T.U. Braunschweig, 2001.		5	H. Irschik et al., J. Antibiot. 1995, 48(1), 31-35.				
		6	Y. A. Elnakady, Dissertation, T.U. Braunschweig, 2001.				
7			y .				
		7					

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.